$16.60
1.72% yesterday
Nasdaq, May 20, 09:50 pm CET
ISIN
US78349D1072
Symbol
RXST

RxSight Inc Stock price

$16.62
+2.42 17.04% 1M
-28.19 62.91% 6M
-17.76 51.66% YTD
-46.02 73.47% 1Y
+3.00 22.03% 3Y
+0.62 3.88% 5Y
+0.62 3.88% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.30 1.84%
ISIN
US78349D1072
Symbol
RXST
Sector

Key metrics

Market capitalization $675.39m
Enterprise Value $458.09m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.09
P/S ratio (TTM) P/S ratio 4.55
P/B ratio (TTM) P/B ratio 2.42
Revenue growth (TTM) Revenue growth 46.69%
Revenue (TTM) Revenue $148.31m
EBIT (operating result TTM) EBIT $-36.86m
Free Cash Flow (TTM) Free Cash Flow $-20.52m
Cash position $229.34m
EPS (TTM) EPS $-0.67
P/E forward negative
P/S forward 4.03
EV/Sales forward 2.73
Short interest 11.06%
Show more

Is RxSight Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

RxSight Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a RxSight Inc forecast:

6x Buy
55%
3x Hold
27%
2x Sell
18%

Analyst Opinions

11 Analysts have issued a RxSight Inc forecast:

Buy
55%
Hold
27%
Sell
18%

Financial data from RxSight Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
148 148
47% 47%
100%
- Direct Costs 42 42
13% 13%
28%
107 107
66% 66%
72%
- Selling and Administrative Expenses 103 103
34% 34%
70%
- Research and Development Expense 37 37
23% 23%
25%
-34 -34
22% 22%
-23%
- Depreciation and Amortization 3.27 3.27
25% 25%
2%
EBIT (Operating Income) EBIT -37 -37
23% 23%
-25%
Net Profit -27 -27
40% 40%
-18%

In millions USD.

Don't miss a Thing! We will send you all news about RxSight Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RxSight Inc Stock News

Neutral
GlobeNewsWire
about 8 hours ago
ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Stifel Virtual Ophthalmology Forum.
Neutral
Seeking Alpha
13 days ago
RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President & Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Steve Lichtman - Oppenheimer David Saxon - Needham & Company Adam ...
Neutral
GlobeNewsWire
20 days ago
ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas.
More RxSight Inc News

Company Profile

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery The company was founded by Robert Grubbs and Daniel Schwartz on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Head office United States
CEO Ronald Kurtz
Employees 498
Founded 1997
Website rxsight.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today